The data on Pfizer's GLP-1 offer early evidence that the injection can be administered less frequently than existing drugs ...
A long-acting shot Pfizer got through a buyout of Metsera appeared “slightly inferior” to Lilly’s market-leading Zepbound in a Phase 2 trial, one analyst said.
To help answer common vaccine questions, we consulted Dr. Stanley Perlman, a professor at the University of Iowa’s Carver ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results